紫杉醇脂质体联合顺铂治疗非小细胞肺癌的近期疗效及安全性分析  

Short-term efficacy and safety analysis of paclitaxel liposome combined with cisplatin in the treatment of non-small cell lung cancer

作　　者：罗杨婧婷 常惠礼[1] 麦露丝[1] LUO Yang-jing-ting;CHANG Hui-li;MAI Lu-si(Department of Pharmacy,Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan 511518,China)

机构地区：[1]广州医科大学附属第六医院/清远市人民医院药学部,511518

出　　处：《中国实用医药》2022年第18期123-126,共4页China Practical Medicine

摘　　要：目的 探讨紫杉醇脂质体联合顺铂治疗非小细胞肺癌(NSCLC)的临床效果及安全性。方法 回顾性分析40例接受化疗治疗的NSCLC患者的临床资料,根据化疗方案的不同分为观察1组和观察2组,每组20例。观察1组患者采用紫杉醇注射液联合顺铂进行化疗,观察2组患者采用紫杉醇脂质体联合顺铂进行化疗。比较两组患者治疗效果,治疗前后肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、鳞状细胞癌抗原(SCC)、细胞角蛋白19片段抗原(CYFRA21-1)]水平,不良反应发生情况。结果 观察1组治疗有效率为55.00%(11/20),观察2组治疗有效率为65.00%(13/20);两组治疗有效率对比差异无统计学意义(P>0.05)。治疗前,两组CEA、CA125、SCC和CYFRA21-1水平比较,差异均无统计学意义(P>0.05);治疗后,两组CEA、CA125、SCC和CYFRA21-1水平均显著低于治疗前,且观察2组CEA(7.13±2.04)μg/L、CA125(42.39±8.22)kU/L、SCC(1.82±0.31)μg/L和CYFRA21-1(6.06±1.48)μg/L均低于观察1组的(10.64±2.82)μg/L、(68.46±15.98)kU/L、(2.47±0.55)μg/L、(7.16±1.52)μg/L,差异有统计学意义(P<0.05)。观察1组不良反应发生率为60.00%(12/20),观察2组不良反应发生率为20.00%(4/20);观察2组不良反应发生率低于观察1组,差异有统计学意义(P<0.05)。结论 紫杉醇脂质体联合顺铂治疗NSCLC患者可以显著降低肿瘤标志物水平,在保障治疗效果的同时减少不良反应的发生,治疗安全性较高,值得推广实施。Objective To discuss the clinical effect and safety of paclitaxel liposome combined with cisplatin in the treatment of non-small cell lung cancer(NSCLC). Methods A total of 40 patients with NSCLC who received chemotherapy were divided into observation group 1 and observation group 2 according to different chemotherapy regimens, with 20 cases in each group. Patients in observation group 1 were treated with paclitaxel injection combined with cisplatin for chemotherapy, while patients in observation group 2 were treated with paclitaxel liposome combined with cisplatin. Both groups were compared in terms of therapeutic effect, and levels of tumor markers [carcinoembryonic antigen(CEA), carbohydrate antigen 125(CA125), squamous cell carcinoma antigen(SCC), cytokeratin 19 fragment(CYFRA21-1)] before and after treatment, and occurrence of adverse reactions. Results The effective rate of observation group 1 was 55.00%(11/20), and the effective rate of observation group 2 was 65.00%(13/20);there was no statistically significant difference in the effective rate of treatment between the two groups(P>0.05). Before treatment, there was no statistically significant difference in the levels of CEA, CA125, SCC and CYFRA21-1 between the two groups(P>0.05). After treatment, the levels of CEA,CA125, SCC and CYFRA21-1 in the two groups were significantly lower than those before treatment in this group;CEA(7.13±2.04) μg/L, CA125(42.39±8.22) kU/L, SCC(1.82±0.31) μg/L and CYFRA21-1(6.06±1.48) μg/L in observation group 2 were lower than(10.64±2.82) μg/L,(68.46±15.98) kU/L,(2.47±0.55) μg/L,(7.16±1.52) μg/L in observation group 1;all the differences were statistically significant(P<0.05). The incidence of adverse reactions in observation group 1 was 60.00%(12/20), and the incidence of adverse reactions in observation group 2 was 20.00%(4/20);the incidence of adverse reactions in observation group 2 was lower than that in observation group 1, and the difference was statistically significant(P<0.05). Conclusion The treatment o

关 键 词：非小细胞肺癌 紫杉醇脂质体 紫杉醇 顺铂 临床疗效 安全性 

分 类 号：R734.2[医药卫生—肿瘤]